Logo image of RERE

ATRENEW INC (RERE) Stock Fundamental Analysis

NYSE:RERE - New York Stock Exchange, Inc. - US00138L1089 - ADR - Currency: USD

2.78  -0.05 (-1.77%)

Fundamental Rating

5

Overall RERE gets a fundamental rating of 5 out of 10. We evaluated RERE against 121 industry peers in the Specialty Retail industry. No worries on liquidiy or solvency for RERE as it has an excellent financial health rating, but there are worries on the profitability. RERE is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year RERE was profitable.
In the past 5 years RERE always reported negative net income.
In multiple years RERE reported negative operating cash flow during the last 5 years.
RERE Yearly Net Income VS EBIT VS OCF VS FCFRERE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -1B -2B

1.2 Ratios

RERE's Return On Assets of 2.37% is in line compared to the rest of the industry. RERE outperforms 56.20% of its industry peers.
RERE has a better Return On Equity (3.39%) than 60.33% of its industry peers.
RERE's Return On Invested Capital of 3.00% is in line compared to the rest of the industry. RERE outperforms 49.59% of its industry peers.
Industry RankSector Rank
ROA 2.37%
ROE 3.39%
ROIC 3%
ROA(3y)-17.29%
ROA(5y)-20.7%
ROE(3y)-22.67%
ROE(5y)-27.41%
ROIC(3y)N/A
ROIC(5y)N/A
RERE Yearly ROA, ROE, ROICRERE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

RERE has a Profit Margin (0.73%) which is comparable to the rest of the industry.
RERE's Operating Margin of 0.84% is in line compared to the rest of the industry. RERE outperforms 42.98% of its industry peers.
RERE's Gross Margin of 11.97% is on the low side compared to the rest of the industry. RERE is outperformed by 91.74% of its industry peers.
In the last couple of years the Gross Margin of RERE has grown nicely.
Industry RankSector Rank
OM 0.84%
PM (TTM) 0.73%
GM 11.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.4%
GM growth 5Y35.7%
RERE Yearly Profit, Operating, Gross MarginsRERE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30 -40

More info and screens

7

2. Health

2.1 Basic Checks

RERE has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for RERE has been reduced compared to 1 year ago.
Compared to 5 years ago, RERE has about the same amount of shares outstanding.
The debt/assets ratio for RERE has been reduced compared to a year ago.
RERE Yearly Shares OutstandingRERE Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
RERE Yearly Total Debt VS Total AssetsRERE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

RERE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z N/A
ROIC/WACC0.37
WACC8.12%
RERE Yearly LT Debt VS Equity VS FCFRERE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B

2.3 Liquidity

RERE has a Current Ratio of 2.92. This indicates that RERE is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 2.92, RERE belongs to the best of the industry, outperforming 92.56% of the companies in the same industry.
RERE has a Quick Ratio of 2.44. This indicates that RERE is financially healthy and has no problem in meeting its short term obligations.
RERE's Quick ratio of 2.44 is amongst the best of the industry. RERE outperforms 94.21% of its industry peers.
Industry RankSector Rank
Current Ratio 2.92
Quick Ratio 2.44
RERE Yearly Current Assets VS Current LiabilitesRERE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

8

3. Growth

3.1 Past

RERE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 164.02%, which is quite impressive.
The Revenue has grown by 26.08% in the past year. This is a very strong growth!
Measured over the past years, RERE shows a very strong growth in Revenue. The Revenue has been growing by 32.94% on average per year.
EPS 1Y (TTM)164.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%269.23%
Revenue 1Y (TTM)26.08%
Revenue growth 3Y28.03%
Revenue growth 5Y32.94%
Sales Q2Q%27.45%

3.2 Future

Based on estimates for the next years, RERE will show a very strong growth in Earnings Per Share. The EPS will grow by 50.92% on average per year.
Based on estimates for the next years, RERE will show a very strong growth in Revenue. The Revenue will grow by 24.64% on average per year.
EPS Next Y50%
EPS Next 2Y50.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year25.23%
Revenue Next 2Y24.64%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
RERE Yearly Revenue VS EstimatesRERE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 5B 10B 15B 20B 25B
RERE Yearly EPS VS EstimatesRERE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 0 -1 -2 -3

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 34.75 indicates a quite expensive valuation of RERE.
Compared to the rest of the industry, the Price/Earnings ratio of RERE is on the same level as its industry peers.
The average S&P500 Price/Earnings ratio is at 26.32. RERE is valued slightly more expensive when compared to this.
RERE is valuated quite expensively with a Price/Forward Earnings ratio of 47.75.
62.81% of the companies in the same industry are cheaper than RERE, based on the Price/Forward Earnings ratio.
RERE is valuated expensively when we compare the Price/Forward Earnings ratio to 22.19, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 34.75
Fwd PE 47.75
RERE Price Earnings VS Forward Price EarningsRERE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

The rest of the industry has a similar Enterprise Value to EBITDA ratio as RERE.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 11.61
RERE Per share dataRERE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as RERE's earnings are expected to grow with 50.92% in the coming years.
PEG (NY)0.69
PEG (5Y)N/A
EPS Next 2Y50.92%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

RERE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATRENEW INC

NYSE:RERE (6/18/2025, 4:10:03 PM)

2.78

-0.05 (-1.77%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustrySpecialty Retail
Earnings (Last)05-20 2025-05-20/bmo
Earnings (Next)08-18 2025-08-18
Inst Owners36.7%
Inst Owner Change4.26%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap616.33M
Analysts85.71
Price Target5.1 (83.45%)
Short Float %1.1%
Short Ratio2.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.09%
Min Revenue beat(2)-1.18%
Max Revenue beat(2)-1%
Revenue beat(4)0
Avg Revenue beat(4)-0.94%
Min Revenue beat(4)-1.18%
Max Revenue beat(4)-0.43%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)58.73%
EPS NQ rev (1m)-16.18%
EPS NQ rev (3m)-16.18%
EPS NY rev (1m)0%
EPS NY rev (3m)-18.18%
Revenue NQ rev (1m)-3.64%
Revenue NQ rev (3m)-3.64%
Revenue NY rev (1m)-1.7%
Revenue NY rev (3m)0.14%
Valuation
Industry RankSector Rank
PE 34.75
Fwd PE 47.75
P/S 0.26
P/FCF N/A
P/OCF N/A
P/B 1.18
P/tB 1.19
EV/EBITDA 11.61
EPS(TTM)0.08
EY2.88%
EPS(NY)0.06
Fwd EY2.09%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS10.88
BVpS2.35
TBVpS2.33
PEG (NY)0.69
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.37%
ROE 3.39%
ROCE 3.8%
ROIC 3%
ROICexc 3%
ROICexgc 3.03%
OM 0.84%
PM (TTM) 0.73%
GM 11.97%
FCFM N/A
ROA(3y)-17.29%
ROA(5y)-20.7%
ROE(3y)-22.67%
ROE(5y)-27.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.4%
GM growth 5Y35.7%
F-ScoreN/A
Asset Turnover3.24
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.92
Quick Ratio 2.44
Altman-Z N/A
F-ScoreN/A
WACC8.12%
ROIC/WACC0.37
Cap/Depr(3y)21.03%
Cap/Depr(5y)18.67%
Cap/Sales(3y)0.55%
Cap/Sales(5y)0.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)164.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%269.23%
EPS Next Y50%
EPS Next 2Y50.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)26.08%
Revenue growth 3Y28.03%
Revenue growth 5Y32.94%
Sales Q2Q%27.45%
Revenue Next Year25.23%
Revenue Next 2Y24.64%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y197.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year39.3%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y266.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y163.53%
OCF growth 3YN/A
OCF growth 5YN/A